<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984877</url>
  </required_header>
  <id_info>
    <org_study_id>AMY-TAVI</org_study_id>
    <nct_id>NCT03984877</nct_id>
  </id_info>
  <brief_title>Impact of Amyloidosis on TAVI Patients</brief_title>
  <acronym>AMY-TAVI</acronym>
  <official_title>Impact of Cardiac Amyloidosis on Patients With Severe Aortic Stenosis Who Undergo Transcatheter Aortic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Javier López Pais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinico Universitario de Santiago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze the prevalence and impact on the prognosis of amyloidosis due to transthyretin in
      patients with severe aortic stenosis who undergo percutaneous aortic valve implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type and design of the study: Multicentric, prospective cohort, observational.

      Number and characteristics of the patients: 321 patients to whom TAVI has been implanted due
      to severe degenerative AS.

      Duration of the study

        -  Recruitment period: All consecutive patients undergoing a non-invasive diagnostic study
           of amyloidosis (scintigraphy with technetium pyrophosphate99 and blood protein
           electrophoresis) will be recruited before discharge, in centers with proven experience,
           will accept non-invasive diagnosis with resonance) and have an implanted percutaneous
           aortic prosthesis for severe aortic stenosis.

        -  Follow-up period: clinical and echocardiographic follow-up will be carried out before
           discharge, in consultation at three, six, twelve and twenty-four months.

      Inclusion: 1 year

      Follow up: 2 years

      Data analysis: 6 months

      Total: 3 years and 6 months

      Events

        -  Main event: cardiovascular events (cardiovascular death, stroke, infarction)

        -  Secondary events: death from any cause, readmission due to heart failure, pacemaker
           implantation, functional class evaluation

      Countries and participating centers: Various Spanish and international centers will be
      invited to participate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Survival after TAVI of patients with amyloidosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pacemaker requirements</measure>
    <time_frame>15 days</time_frame>
    <description>Number of patients with amyloidosis who received pacemaker after TAVI.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Valve Stenoses, Aortic</condition>
  <condition>Amyloidosis Cardiac</condition>
  <arm_group>
    <arm_group_label>Amyloidosis</arm_group_label>
    <description>TAVI patients with diagnosis of amyloidosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Amyloidosis</arm_group_label>
    <description>TAVI patients without diagnosis of amyloidosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnosis of amyloidosis</intervention_name>
    <description>Scintigraphy and protein electrophoresis</description>
    <arm_group_label>Amyloidosis</arm_group_label>
    <arm_group_label>Non-Amyloidosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include patients of legal age, recruited in the hospitalization area or from
        outpatient clinics, who meet the following requirements: diagnosis of severe aortic
        stenosis by conventional echocardiographic criteria (maximum speed&gt; 4m / s, medium
        transvalvular gradient&gt; 40mmHg, area &lt;1cm2).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aortic valve replacement with a percutaneous prosthesis due to severe aortic stenosis
             after evaluation by the Heart Team.

          -  Ability to understand and sign informed consent.

          -  They do not meet any of the exclusion criteria.

        Exclusion Criteria:

          -  Death as a complication of the procedure during hospitalization.

          -  Associated mitral valve disease requiring intervention

          -  TAVI valve-in-valve implant.

          -  Does not sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Ramón Gonzalez Juantey, M.D. Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Complexo Hospitalario Universitario de Santiago de Compostela</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diego Lopez Otero, M.D.</last_name>
    <phone>981 95 00 00</phone>
    <email>Diego.Lopez.Otero@sergas.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javier López Pais, M.D. Ph.D.</last_name>
    <phone>981 95 00 00</phone>
    <email>javierlopezpais@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15703</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier López Pais, M.D.</last_name>
      <phone>981 95 00 00</phone>
      <email>javierlopezpais@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Diego López Otero, M.D. Ph.D.</last_name>
      <phone>981 95 00 00</phone>
      <email>Diego.Lopez.Otero@sergas.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinico Universitario de Santiago</investigator_affiliation>
    <investigator_full_name>Javier López Pais</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Cardiac amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03984877/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

